OPCH

Option Care Health is a quality compounder in home infusion: revenue grew 13.0% to $5.65B in FY2025, extending a clean four-year ramp from $3.44B in FY2021, and the company throws off real cash — $258M of operating cash flow against just $41M of capex. ROE of 15.7% on a 1.61x liabilities/equity stack is healthy, and management is returning capital aggressively ($310M of buybacks shrunk the share count 5.4% YoY). At a 17.3x P/E and 0.6x P/S, the stock is not demanding — it screens as a fair price for a steady mid-single-digit-margin services business.

The problem is the trajectory of profitability, and the MD&A is unusually direct about it. Gross margin compressed 100 bps to 19.3% from 20.3%, with management attributing the slip to 'mix, including certain higher cost therapies included within chronic growth (including rare and orphan therapies) as well as biosimilar adoption.' Critically, management explicitly guides that 'these dynamics to negatively impact gross profit by $25 million to $35 million in 2026' — that is a self-disclosed $25-35M headwind on a base of $1.09B, i.e. 2-3% of gross profit before any offsetting growth. Net income actually declined 2.0% in FY2025 despite 13% revenue growth, and operating cash flow fell 20.1% — the disconnect between top-line momentum and bottom-line/cash conversion is the central concern.